Loading...
BIOLASE, Inc.
BIOL•NASDAQ
Healthcare
Medical - Devices
$0.02
$0.004(27.39%)

The company's financials show resilient growth, with revenue advancing from $10.92M in Q3 2023 to $11.55M in Q2 2024. Gross profit remained healthy with margins at 40% in Q2 2024 compared to 34% in Q3 2023. Operating income hit -$3.22M last quarter, sustaining a consistent -28% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$3.22M. Net income rose to -$2.80M, while earnings per share reached -$0.08. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan